Covance aquires antibodies product line of Sternberger Monoclonals

29-Jun-2005

Covance Inc. announced that its wholly owned subsidiary, Covance Research Products Inc., has acquired the complete line of antibodies developed by Sternberger Monoclonals Inc. (SMI), of Lutherville, MD. These products are ideally suited for immunohistochemical studies and complement Covance's extensive suite of antibody products for neuroscience and neurodegenerative disease research and discovery.

As a subsidiary of one of the world's largest and most comprehensive drug development services companies, Covance Research Products is uniquely positioned to support the Sternberger antibodies suite. The company supports biomedical scientists with a select catalog of antibody products, including leading products in the areas of neuroscience, epitope tags, and cell biology. In addition, for the last several years, Covance has produced the Sternberger antibodies under contract for SMI.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous